Skip to main content
EHL
ไทย

Hospital information

EHL BIO Hospital (EHL Cell Clinic): verifiable hospital information

A specialist medical clinic (clinic level / 의원) in Seoul, designated by the Korean Ministry of Health and Welfare as the first clinic-level advanced regenerative medicine institution, with an affiliated research centre and GMP laboratory. Everything here is sourced, and unverified points are labelled as such.

About the hospital and its research centre

EHL BIO describes itself as an R&D institute founded to search for solutions to diverse diseases and ageing, developing regenerative medicine, stem cell therapeutics (isolation, banking and culture) and immune cell therapeutics.

The hospital's affiliated research centre states that its research spans neurological disease, osteoarthritis, circulatory and metabolic disease and autoimmune disease, as well as anti-ageing, health improvement, alopecia and aesthetic care.

The above summarises what the hospital publishes about itself. It is not a regulatory assessment, and it does not mean treatment for these conditions is approved in Thailand.

Strengths stated by the hospital

01

Technology for stem cell harvest, isolation and culture

  • The hospital's affiliated research centre states it holds cell-culture know-how and patent rights.
  • It states it holds independent cell-proliferation know-how.
  • It claims a higher stem cell number and activity than competitors, with yield up to 1,000 times higher (an internal comparison by the institution, not an independently audited figure).
  • It states it minimises the difference in cell survival before and after cryopreservation, and that a repeated intravenous injection clinical trial is under way, described as the first in Korea.

02

Manufacturing facilities ensuring GMP

  • States it developed a culture, banking and quality-control system for autologous stem cells.
  • States it maintains class 100 clean facilities.
  • States it operates a stem cell banking system with cryopreservation tanks.
  • States a yearly culture capacity of 6,000 lots.

03

Research and hospital network

  • States joint stem cell research with universities in Korea and abroad.
  • States collaborations with more than 100 hospitals in Korea.
  • States provision through more than 50 collaborating overseas hospitals (legal scope and indications differ by country).

04

Development of diverse cell therapeutics

  • Exosome therapeutics.
  • Products using stem cell conditioned media.
  • Immune cells such as NK cells, T cells, dendritic cells and iNKT cells.

05

Experience in cosmetics development

  • States it offers cosmetic products for customers seeking skin care.
  • States it launched a product containing 97% human adipose-derived stem cell conditioned media.

Information sources

CEO message

“With the best technology, I think about human and tomorrow.” The CEO message states that EHL BIO specialises in developing stem cell and immune cell therapeutics for diverse diseases and ageing.

The hospital's affiliated research centre states that it develops next-generation biopharmaceuticals such as cell therapeutics and exosomes, based on the research and experience of its doctors and scientists, and aims to advance regenerative medicine for better quality of life.

EHLBIO Co. — CEO MD Hong-gi Lee

Information sources

History and milestones, 2012–2024

  1. 2024

    • KDSTEM selected for the 2024 Korean Fund for Regenerative Medicine (KFRM) programme.
    • ADSTEM IND application submitted for a Phase 3 clinical trial in atopic dermatitis.

  2. 2023

    • KDSTEM IND approved and Phase 1 clinical trial in chronic kidney disease initiated.
    • ADSTEM completed its Phase 2 clinical trial in atopic dermatitis.

  3. 2022

    • KDSTEM selected for the 2022 KFRM programme.
    • MOU for advanced regenerative medicine signed (Hwasun Chonnam National University Hospital, Gangnam Severance Hospital, New Breath Hospital).
    • EHLBio Cell Center relocated to Apgujeong.

  4. 2021

    • Permission for human cell management business (No. 1).
    • CPC (Cell Processing Center) permission, stated as the first in Korea.
    • MOUs for advanced regenerative medicine signed (Chungnam National University Hospital, Dankook University Hospital, Chonnam National University Hospital, Seoul Songdo Hospital).

  5. 2020

    • Establishment of subsidiary EHL CELLTECH (January).

  6. 2019

    • Phase 2 clinical trial approval for ADSTEM (stated as the first in Korea for autologous adipose-derived cells given intravenously).
    • Opening of a Cambodian branch and a hospital specialising in cell therapy (joint company).
    • Completion of the 2nd GMP centre (500 lots per month).
    • Opening of a local office in Indonesia.

  7. 2018

    • Phase 2 clinical trial application for ADSTEM.
    • Establishment of the Stem-heal Society.

  8. 2017

    • Dec 2017: Phase 1 clinical trial completed for ADSTEM.
    • Nov 2017: cooperation signed with ODA Clinic in Japan.
    • Sep 2017: representative office established in Vietnam.
    • Jul 2017: CPC approval by the Japanese Ministry of Health, Labour and Welfare.
    • Jun 2017: safety testing completed for the immune cell preclinical test.

  9. 2016

    • Selected for the Start-up Growth Technology Development Project by the Ministry of SMEs and Startups.
    • Preclinical testing for immune cells.
    • Clinical Phase 1 approval.

  10. 2015

    • Application for clinical trials of autologous adipose-derived stem cells, vascular injection, atopic dermatitis.
    • Research institute expanded and relocated.
    • Certified as a Venture Company (Mar 2015).

  11. 2014

    • Company research centre registered.
    • Selected for the Industry-Academic Cooperation Technology Development Project of the Ministry of SMEs and Startups.
    • Preclinical testing of ADSTEM injection for atopic dermatitis.

  12. 2013

    • Launch of stem cell culture fluid cosmetics, hair growth testing with culture fluid, and research on culture media for healthcare (April).

  13. 2012

    • EHL Bio, Co., Ltd. founded (February).

Information sources

Global EHL: listed medical centres

This is the list of medical centres EHL BIO names on its Global EHL page at the retrieval date. No centre in Thailand is listed there. Service scope and legal requirements differ by country.

  • Tokyo · Japan
  • Nagoya · Japan
  • Fukuoka · Japan
  • Beijing · China
  • Jinan · China
  • Shenzhen · China
  • Hanoi · Vietnam
  • Hai Phong · Vietnam
  • Ho Chi Minh · Vietnam
  • Phnom Penh · Cambodia
  • Makati · Philippines
  • Jakarta · Indonesia
  • Singapore (Atlas) · Singapore

Information sources

About the hospital

An advanced regenerative medicine institution in the Republic of Korea with an affiliated research centre and laboratory.

EHL BIO Hospital (EHL Cell Clinic) is a specialist medical clinic (clinic level / 의원) in Seoul, Republic of Korea, designated by the Korean Ministry of Health and Welfare (MOHW) as an advanced regenerative medicine institution (첨단재생의료 실시기관) — the first at clinic level.

Within the institution, the affiliated EHL BIO research centre and GMP cell-manufacturing laboratory handle stem cell, immune cell and stem cell conditioned media work, including the published research and patents.

The official website organises information into cell technology sections, a disease topic section (CURE), research and development (R&D), hospital information, partnership, and news and contact (SUPPORT).

EHL Thailand is the hospital's Thai-language information site. It summarises and explains this public information for educational purposes, always citing the source, and never claiming treatment outcomes beyond published evidence.

Information sources

Global EHL

International network and partnerships as published by the hospital.

The EHL BIO website includes Global EHL and Partnership sections describing its approach to international collaboration.

Partner details, countries of operation and the scope of collaboration change over time, so EHL Thailand does not list partners or per-country legal scope until it can be verified at the source.

Readers seeking business partnership information should use the contact channels listed on the hospital website.

Information sources

History & Milestones

The institutional timeline as published in the company History section.

The 2012–2024 timeline shown above summarises the History section of the hospital website, retrieved 3 September 2026.

These entries are what the hospital publishes about itself — trial approvals, licences and expansion — not an assessment by Thai regulators.

If any entry no longer matches the source page, we will correct it and record a new verification date.

Information sources

Location & Contact

The hospital's location and published contact channels.

The hospital is located at EHL Building, 136 Apgujeong-ro, Gangnam-gu, Seoul 06029, Republic of Korea, as published in the Location and Contact Us sections of its website.

EHL Thailand does not yet publish a Thai office address, phone number or email until official contact details are confirmed; showing unverified contact details could send patients to the wrong channel.

For information questions, use the consultation form on this site, which currently helps you prepare questions before seeing a doctor.

Information sources

Medical and scientific experts

EHL BIO expert information is summarised from the hospital's public website and is published by the institution itself, not an endorsement by any Thai regulator. Reviewers of this site's content are shown as they actually are, and physician names will appear once verifiable.

EHL BIO experts (Korea)

MD Hong-gi Lee (CEO)

Chief Executive Officer, EHLBIO Co., Ltd.

Publicly named

Direction of stem cell, immune cell and exosome therapeutics development

  • Name and title appear on EHL BIO's CEO message page (listed as MD).
  • The hospital's affiliated research centre states that its biopharmaceutical development draws on the research and experience of its in-house doctors and scientists.
  • EHL Thailand has not independently checked Korean medical licence records.
EHL BIO — CEO Message

EHL BIO Stem Cell Research Institute

Stem cell therapeutics research and development team

Team level, no named individual

ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes

  • The hospital's affiliated research centre states ADSTEM Phase 1–2 trials were conducted and a KDSTEM Phase 1 trial started in Korea.
  • The hospital's affiliated research centre states it holds know-how and patents in stem cell isolation and culture.
  • Individual researcher names are not published publicly, so this is shown at team level.
EHL BIO — Stem cell treatment

EHL BIO GMP Centre Quality Team

Manufacturing, quality control and cell banking

Team level, no named individual

Class 100 clean facilities, cell banking systems and pre/post-cryopreservation quality control

  • The hospital's affiliated research centre states a culture capacity of 6,000 lots per year.
  • The institution lists manufacturing-related permissions in Korea (see its GMP centre page).
  • These are Korean approvals and are not authorisation to treat disease in Thailand.
EHL BIO — GMP center

EHL BIO Immune Cell Research Team

Immune cell therapy research and immune cell banking

Team level, no named individual

Keycell-IM programme (T, NK, iNKT and dendritic cells); the hospital's affiliated research centre states lung cancer as the preclinical target

  • The institution describes apheresis collection, activation culture and quality control.
  • This work remains investigational and is not approved cancer treatment.
EHL BIO — Immune Cell Therapeutics

EHL Thailand content authors and reviewers

EHL Thailand Medical Information Team

Writes and reviews disease pages and stem cell topics

Team level, no named individual

Evidence levels, regulatory status, and separating hospital information from medical information

  • Sources are PubMed, ClinicalTrials.gov, WHO and EHL BIO public materials.
  • Named physician reviewers are pending verification; name, specialty and licence number will be shown once verified.

EHL Thailand Research Desk

Reviews articles, research summaries and clinical trial status

Team level, no named individual

Careful reading of study results, including sample size, trial phase and limitations

  • Checks that every claim links to an openly viewable source.
  • Never uses cure or guarantee language, or claims approvals without documentation.

Checkable credentials behind the team

Compiled from the public pages of ehlbio.co.kr so readers can verify each item themselves. All are Korean records and are not authorisation to treat disease in Thailand.

Published research papers6

  • Human adipose tissue derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation (2016)
  • Human Adipose Tissue Derived Mesenchymal Stem Cells Attenuate Atopic Dermatitis by Regulating the Expression of MIP2, miR122a-SOCS1 Axis, and Th1/Th2 Responses (2018)
  • Urine-Derived Stem Cell-Secreted Klotho Plays a Crucial Role in the HK-2 Fibrosis Model by Inhibiting the TGF-β Signaling Pathway (2022)
  • Production enhancement of human adipose-derived mesenchymal stem cells by low-intensity ultrasound stimulation (2022)
  • In vivo safety and biodistribution profile of Klotho-enhanced human urine-derived stem cells for clinical application (2023)
  • Combinational Pulsing of TAAs Enforces Dendritic Cell-Based Immunotherapy through T-Cell Proliferation and Interferon-γ Secretion in LLC1 Mouse Model (2024)
EHL BIO — Other treatments

Registered patents11

  • No. 10-1172638 — Novel thiazolidinedione derivatives and uses thereof
  • No. 15771853 — Composition comprising cells treated with a 15-PGDH inhibitor or culture thereof and use thereof
  • No. 10-2016-0007049 — Liposuction and SVF separation kit
  • No. 10-2016-0139967 — Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof
  • No. 10-2018-0001149 — Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof
  • No. 10-2018-0030906 — Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof
EHL BIO — Patents and Research Papers

Korean manufacturing permissions4

  • Clinical approval for stem cell treatment in atopic dermatitis (the source page states Phase 2 in progress at time of publication).
  • CPC (Cell Processing Center) permission from the Japanese Ministry of Health, Labour and Welfare.
  • First human cell management business licence in Korea.
  • First CPC permission in Korea.
EHL BIO — GMP center

Certificates and trademarks5

  • EHLBio Research Institute certification
  • European EHLBio trademark
  • Indonesian EHLBio trademark rights
  • 키셀 trademark registration certificate
  • Kissel trademark registration certificate
EHL BIO — Other treatments

An EHL BIO or EHL Thailand doctor or scientist? Submit your real biography, qualifications and licence to replace the team-level profiles above with verified details.

Submit expert profile

Editorial review policy: read the editorial policy

Not sure whether this applies to your case?

Send your questions and initial information through the form. Our team will help prepare your case for an individual assessment with EHL Cell Clinic in Korea.

Consult EHL Thailand